Zensar Technologies Ltd - 504067 - Update On Merge Of US Subsidiary
Zensar Technologies announced the completion of filings for the merger of its US-based wholly-owned subsidiary, Bridgeview Life Sciences LLC, with Zensar Technologies Inc. This merger will become effective on August 1, 2026. Filings for the merger of another subsidiary, M3BI LLC, are currently underway.
Jul 31 2026 14:48:51
Zensar Technologies Ltd - 504067 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Zensar Technologies has made available the audio recording of its Q1 FY27 earnings call, which was held on July 30, 2026, discussing the quarter ended June 30, 2026. Investors can access the recording on the company's website under the Investors Corner section.
Jul 30 2026 11:20:29
Zensar Technologies Ltd - 504067 - Board Meeting Intimation for Considering And Approving The Un-Audited Financial Results For The Quarter Ended June 30, 2026
Zensar Technologies board will convene on July 29, 2026, to approve its Q1 FY27 financial results. This meeting will review the company's performance for the quarter ended June 30, 2026.
Jul 21 2026 16:29:12
Zensar Technologies Ltd - 504067 - In Compliance With Regulation 36(1)(B) Of The SEBI Listing Regulations, A Letter Providing Weblink Of Company'S Website Where The Integrated Annual Report For FY 2025-26 Has Been Uploaded And The Same Can Be Accessed By The Shareholders.
Zensar Technologies has fixed July 17, 2026, as the record date for its final dividend for FY2025-26. Eligible shareholders will receive the dividend payment on or before August 29, 2026.
Jul 08 2026 16:23:47
Read More